Tag

Abfero

AbFero Pharmaceuticals Announces Funding From Cure Parkinson’s for Lead Compound SP-420

AbFero Ltd., a subsidiary of UF startup AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, announced the award of a grant from Cure Parkinson's for the development of their lead, brain-penetrant iron chelating agent, SP-420, as a disease modifying therapy for Parkinson's disease (PD).

AbFero to Receive € 2M Eurostars Funding for Parkinson’s Disease Therapy

AbFero Ltd., a subsidiary of UF startup AbFero Pharmaceuticals, Inc., a privately-held clinical-stage pharmaceutical company dedicated to treating diseases of iron overload, announced the funding of approximately € 2M from EUREKA Eurostars for the development of iron-chelating compounds including their lead agent, SP-420, as a disease-modifying therapy for Parkinson's disease.
X